Ads by Google
Women account for half the cardiovascular mortality in the United States, but it is unknown why more women do not sign up for these clinical trials.
ISTA Pharmaceuticals presented results from two Phase III clinical trials of Xibrom (bromfenac sodium ophthalmic solution) QD (once- daily) formulation.
Akela Pharma announced positive final results from its pilot GHRH Phase II study. Within only 4 weeks of treatment, Akela GHRH induced a highly significant stimulation of endogenous growth hormone (GH) secretion and a marked increase of circulating insulin-like growth factor(IGF-1) as compared to placebo in patients with chronic kidney disease.
Ensuring that clinical research studies include a diverse population of participants is important because type 2 diabetes and a host of other diseases affect ethnic minority groups differently.
Nabi Biopharmaceuticals successfully completed Phase 2b trial of NicVAX (Nicotine Conjugate Vaccine).
Abbott's SIMCOR, an investigational, fixed-dose combination of Abbott's proprietary extended-release niacin, Niaspan, and simvastatin met its primary endpoint of lowering plaque-promoting non-HDL cholesterol.
Regado Biosciences presented data from a randomized, double-blind, placebo-controlled Phase Ic study of REG1 Anticoagulation System.
Epeius Biotechnologies Corporation has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States.
The results of a large multi-center research trial of a blood substitute for patients with life-threatening trauma and blood loss show no difference in survival between patients receiving the blood substitute, PolyHeme.
Regado Biosciences enrolled the first patient in a multi-center, open-label, randomized Phase IIa clinical study, named REVERSAL-PCI, of its REG1 Anticoagulation System.
Following advice from an independent Data Safety Monitoring Board, a major clinical trial in cardiac surgery was stopped by the lead researchers.
Revotar Biopharmaceuticals announced first positive results from an investigator driven open labelled Phase IIa pilot study in 14 patients with stable COPD.
VIA Pharmaceuticals will soon initiate a third Phase II clinical trial for VIA-2291, its lead compound.
Sirion Therapeutics announced positive preliminary results from its Phase III difluprednate (ST-601) program.
CryoCath announced positive twelve month follow up data from the second and final cohort of 18 patients treated during the feasibility stage of its STOP AF IDE trial.
Nventa Biopharmaceuticals Corporation has completed enrollment of the first cohort in its Phase 1 clinical trial to assess the safety and tolerability of new HspE7 in patients with cervical intraepithelial neoplasia.
An independent data safety monitoring board found no safety issues and recommended continuation of Vical Incorporated's Phase 2 trial of a DNA vaccine against cytomegalovirus.
MIGENIX has been notified by its partner for the dermatologic applications of omiganan, Cutanea Life Sciences, that a recently completed Phase II rosacea study has demonstrated positive results
Tezampanel was shown in an independent study to be effective in reversing or preventing muscle spasticity and rigidity in a rat model of spinal ischemia.
Cutanea Life Sciences announced positive results from its completed Phase II clinical trial of Omiganan.
Exelixis recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted.
Dey L.P. will present data from two safety studies that were included as part of the New Drug Application (NDA) filing to FDA for Perforomist Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist Inhalation Solution with tiotropium for the treatment of COPD.
First patient has been dosed in Peregrine Pharmaceuticals's clinical trial designed to evaluate the safety and pharmacokinetics of bavituximab.
PEAK Surgical announced results from a preclinical study evaluating its PEAK Pulsed Plasma Technology in the healing of surgical incisions compared with standard electrosurgery and surgical scalpels.
PTC Therapeutics announced encouraging data from a Phase 2 clinical trial of PTC124 in pediatric patients with cystic fibrosis (CF) due to a nonsense mutation. These pediatric results and additional information emerging from long-term studies support the existing data from prior short- term studies in adult CF patients. These studies show that treatment with PTC124 results in statistically significant improvements in a measure of the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Isis Pharmaceuticals announced new results from its Phase 2 clinical trial of ISIS 301012 in patients with heterozygous familial hypercholesterolemia (HeFH) on stable maximally tolerated lipid-lowering therapies.
Cerimon Pharmaceuticals has initiated a Phase I clinical study of a novel diclofenac sodium patch, the Company's lead pain asset.
ADVENTRX Pharmaceuticals announced results from its Phase 2b clinical trial of ANX-510, or CoFactor, for the treatment of metastatic colorectal cancer.
Nektar Therapeutics presented positive results from Phase 1 and preclinical studies of NKTR-118 (oral PEG-naloxol).
Metabolex has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.
